Advanced in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED)

Veronique Kerlan

2 Maréchal Foch Avenue, 
Brest, FR 
Advanced in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED)
2 Maréchal Foch Avenue, 
Brest, FR 
OverviewLocationsClinical Research

Overview

Veronique Kerlan practices in Brest, France. Ms. Kerlan is rated as an Advanced expert by MediFind in the treatment of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED). Her top areas of expertise are Adrenal Cancer, Autoimmune Polyglandular Syndrome Type 2, Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED), Hypercalcemia, and Hormone Replacement Therapy (HRT).

Her clinical research consists of co-authoring 72 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED).

Gender
Female

Locations

2 Maréchal Foch Avenue, Brest, 29200, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Validation of a Predictive Risk Equation for Type 2 Diabetes in Children With Diabetes to Achieve a Predictive Diagnostic Biochip for the Early Detection of Individuals at Risk in Families.
Validation of a Predictive Risk Equation for Type 2 Diabetes in Children With Diabetes to Achieve a Predictive Diagnostic Biochip for the Early Detection of Individuals at Risk in Families.
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Other
Study Phase: Not Applicable
Multicentre Randomized Cross-over Study Assessing in Type 1 Diabetic Patients With Pump Insulin the Non-inferiority of Glycemic Control Obtained With the Algorithms Tested in DIABRASPORT Versus the Rest Period Without Physical Activity
Multicentre Randomized Cross-over Study Assessing in Type 1 Diabetic Patients With Pump Insulin the Non-inferiority of Glycemic Control Obtained With the Algorithms Tested in DIABRASPORT Versus the Rest Period Without Physical Activity
Enrollment Status: Completed
Publish Date: April 08, 2021
Intervention Type: Device, Behavioral
Study Phase: Not Applicable
View 1 Less Clinical Trial

72 Total Publications

French expert consensus statement on diagnosis and MANAGEMENT of PRIMARY HYPERPARATHYROIDISM.
French expert consensus statement on diagnosis and MANAGEMENT of PRIMARY HYPERPARATHYROIDISM.
Journal: Annales d'endocrinologie
Published: September 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kerlan's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 42 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile